<html>

<head>
<meta content="text/html; charset=utf-8" />


<title>M2950303.DOC;1</title>


</head>

<body>



<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">UNITED STATES </font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">SECURITIES AND
EXCHANGE COMMISSION</font></p>

<p align=center style="margin:0in;margin-bottom:.25in;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">WASHINGTON,
D.C. 20549</font></p>

<p align=center style="margin:0in;margin-bottom:.25in;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">FORM
8-K</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">CURRENT REPORT
PURSUANT</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">TO SECTION 13 or
15(d) OF THE</font></p>

<p align=center style="margin:0in;margin-bottom:12.0pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">SECURITIES
EXCHANGE ACT OF 1934</font></p>

<p align=center style="margin:0in;margin-bottom:.25in;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Date
of report (Date of earliest event reported): May 14, 2012</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Medytox Solutions,
Inc.</font></p>

<p align=center style="margin:0in;margin-bottom:12.0pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(Exact
Name of Registrant as Specified in Its Charter)</font></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Nevada</font></p>

<p align=center style="margin:0in;margin-bottom:12.0pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(State
or Other Jurisdiction of Incorporation)</font></p>

<div align=center>

<table border=0 cellpadding=0 cellspacing=0 style="margin-left:0pt;width:0px;">
 <tr>
  <td valign=top width=48% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">000-54346</font></p>
  </td>
 <td valign=top width=52% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">54-2156042</font></p>
  </td>
 </tr>
<tr>
  <td valign=top width=48% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(Commission File
  Number)</font></p>
  </td>
 <td valign=top width=52% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(I.R.S. Employer
  Identification No.)</font></p>
  </td>
 </tr>
</table>

</div>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<div align=center>

<table border=0 cellpadding=0 cellspacing=0 style="width:0px;">
 <tr>
  <td valign=top width=77% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">400 S. Australian
  Avenue, Suite 800, West Palm Beach, Florida</font></p>
  </td>
 <td valign=top width=23% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">33401</font></p>
  </td>
 </tr>
<tr>
  <td valign=top width=77% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(Address of
  Principal Executive Offices)</font></p>
  </td>
 <td valign=top width=23% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(Zip Code)</font></p>
  </td>
 </tr>
</table>

</div>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<div align=left><table border=0 cellpadding=0 cellspacing=0 style="width:0px;">
 <tr>
  <td valign=top width=100% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(561) 855-1626</font></p>
  </td>
 </tr>
<tr>
  <td valign=top width=100% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(Registrant&#8217;s
  Telephone Number, Including Area Code)</font></p>
  </td>
 </tr>
</table></div>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<div align=left><table border=0 cellpadding=0 cellspacing=0 style="width:0px;">
 <tr>
  <td valign=top width=100% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr>
  <td valign=top width=100% style="padding:0in 0in 0in 0in;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">(Former Name or
  Former Address, if Changed Since Last Report)</font></p>
  </td>
 </tr>
</table></div>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</font></p>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face=Wingdings lang=EN-US style="font-size:12.0pt;">o</font><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;"> Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)</font></p>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face=Wingdings lang=EN-US style="font-size:12.0pt;">o</font><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;"> Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face=Wingdings lang=EN-US style="font-size:12.0pt;">o</font><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;"> Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>

<p align=left style="margin:0in;margin-bottom:12.0pt;text-align:left;"><font face=Wingdings lang=EN-US style="font-size:12.0pt;">o</font><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;"> Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>




<p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Section 1 &#8211;
Registrant's Business and Operations</font></b></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;text-indent:.5in;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Item
1.01.&#160; Entering into a Material Definitive Agreement </font></b></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">On May 14,
2012, Medytox Solutions, Inc. (&quot;Medytox&quot;) borrowed $550,000 from TCA
Global Credit Master Fund, LP (the &quot;Lender&quot;) pursuant to the terms of
the Senior Secured Revolving Credit Facility Agreement, dated as of April 30,
2012 (the &quot;Credit Agreement&quot;), among Medytox, Medytox Medical
Marketing &amp; Sales, Inc. (&quot;Medytox Medical&quot;), Medytox Diagnostics,
Inc. (&quot;Diagnostics&quot;), PB Laboratories, LLC (&quot;PB Labs&quot;) and
the Lender.&#160; The funds will be used for general corporate purposes.&#160; Under the
Credit Agreement, Medytox may borrow up to an amount equal to the lesser of 80%
of its Eligible Accounts (as defined in the Credit Agreement) and the revolving
loan commitment, which initially is $550,000.&#160; Medytox may request that the
revolving loan commitment be raised by various specified amounts at specified
times, up to a maximum of $4,000,000.&#160; In each case, the decision to grant any
such increase in the revolving loan commitment is in the Lender's sole
discretion.&#160; The loan matures on the earlier of November 30, 2012, subject to a
six-month extension at the request of Medytox, or upon 60 days written notice
by the Lender.&#160; The maturity date may also be extended, in the Lender's sole
discretion, in connection with an increase in the revolving loan commitment.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The loan bears
interest at the rate of 12% per annum.&#160; In addition, Medytox will pay certain
fees, as set forth in the Credit Agreement.&#160; Medytox also issued to the Lender
40,000 shares of its restricted common stock as a fee for corporate advisory
and investment banking services provided by the Lender.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The loan is
guaranteed by Medytox Medical, Diagnostic and PB Labs, subsidiaries of
Medytox.&#160; It is also secured by a pledge of substantially all of the assets of
Medytox, Medytox Medical, Diagnostic and PB Labs.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Credit Agreement
imposes certain restrictions on Medytox, including on its ability to (i) incur
any Funded Indebtedness (as defined in the Credit Agreement), (ii) incur liens,
(iii) make investments, (iv) permit a Change in Control (as defined in the
Credit Agreement) or dispose of all or substantially all of its assets, (v)
make capital expenditures not in the ordinary course of its business, (vi)
issue or distribute capital stock, (vii) make distributions to its
shareholders, (viii) engage in any line of business other than the business
engaged in on the date of the Credit Agreement and businesses reasonably
related thereto, and (ix) enter into transactions with any affiliates except in
the ordinary course of business and upon fair and reasonable terms that are no
less favorable to Medytox than it would obtain in an arm-length's basis with a
non-affiliate.&#160; Each of these restrictions is subject to certain exceptions, as
specified in the Credit Agreement.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">The loan may
be accelerated upon the occurrence and during the continuation of an Event of
Default (as defined in the Credit Agreement), including nonpayment of amounts
owed, misrepresentation, failure to perform under the Credit Agreement or
related documents, default under certain other obligations, events of bankruptcy,
the entry of a judgment in excess of certain specified amounts, the occurrence
of a Material Adverse Effect (as&#160; defined in the Credit Agreement), the
occurrence of a Change in Control (as defined in the Credit Agreement), certain
impairments of collateral, and the determination in good faith by the Lender
that the prospect for payment or performance of the Obligations (as defined in
the Credit Agreement) is impaired for any reason.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">There are no
material relationships between Medytox or any of its affiliates and the Lender,
other than with respect to the Credit Agreement.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">The foregoing
is qualified in its entirety by reference to the Credit Agreement, a copy of
which is filed herewith as Exhibit 10.1, the revolving promissory note, a copy
of which is filed herewith as Exhibit 10.2, the Guaranty Agreements, copies of
which are filed herewith as Exhibits 10.3, 10.4 and 10.5, and the Security
Agreements, copies of which are field herewith as Exhibits 10.6, 10.7, 10.8 and
10.9.</font></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-align:justify;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Section 2 &#8211; Financial Information</font></b></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-align:justify;text-indent:.5in;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Item 2.03. Creation of a Direct Financial Obligation or
an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</font></b></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">The information set forth above in Item 1.01 is
incorporated by reference.</font></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Section 9 &#8211; Financial
Statement and Exhibits</font></b></p>

<p style="margin:0in;margin-bottom:12.0pt;text-align:justify;text-indent:.5in;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Item 9.01.
Financial Statements and Exhibits</font></b></p>

<p style="margin:0in;margin-bottom:12.0pt;page-break-after:avoid;text-align:justify;text-indent:.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">(d)&#160; Exhibits</font></p>

<div align=left><table border=0 cellpadding=0 cellspacing=0 style="border-collapse:collapse;width:0px;">
 <tr style="height:22.05pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:22.05pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;page-break-after:avoid;text-align:center;"><u><font face="Times New Roman,serif" style="font-size:12.0pt;">Exhibit Number</font></u></p>
  </td>
 <td valign=top width=50% style="height:22.05pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><u><font face="Times New Roman,serif" style="font-size:12.0pt;">Description</font></u></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.1</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Senior Secured Revolving Credit Facility Agreement, dated
  as of April 30, 2012, among Medytox Solutions, Inc., Medytox Medical
  Marketing &amp; Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC
  and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.2</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Revolving Promissory Note, dated April 30,&#160; 2012, issued
  by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.3</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement, dated as of April 30, 2012, by Medytox
  Medical Marketing &amp; Sales, Inc. in favor of TCA Global Credit Master
  Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.4</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement. dated as of April 30, 2012, by Medytox
  Diagnostics, Inc. in favor of TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.5</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement, dated as of April 30, 2012, by PB
  Laboratories, LLC in favor of TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.6</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Solutions, Inc. and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.7</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Medical Marketing &amp; Sales, Inc. and TCA Global Credit Master
  Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.8</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Diagnostics, Inc. and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.9</font></p>
  </td>
 <td valign=top width=50% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between PB
  Laboratories, LLC and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table></div>




<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;page-break-after:avoid;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">SIGNATURES</font></b></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-align:justify;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Date: May 18, 2012&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; MEDYTOX
SOLUTIONS, INC.</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">/s/
William G. Forhan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></u></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; William
G. Forhan,</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; CEO
and Chairman</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (principal
executive officer)</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>








<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">EXHIBIT INDEX</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></b></p>

<p align=center style="margin:0in;margin-bottom:.0001pt;text-align:center;"><b><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></b></p>

<p style="margin-bottom:12.0pt;margin-left:0in;margin-right:0in;margin-top:0in;text-align:justify;"><u><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Exhibit No.</font></u><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">Description&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></u></p>

<div align=left><table border=0 cellpadding=0 cellspacing=0 style="border-collapse:collapse;width:0px;">
 <tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p align=left style="margin:0in;margin-bottom:.0001pt;text-align:left;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.1</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Senior Secured Revolving Credit Facility Agreement, dated
  as of April 30, 2012, among Medytox Solutions, Inc., Medytox Medical
  Marketing &amp; Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC
  and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:43.65pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:43.65pt;padding:0in 5.4pt 0in 5.4pt;">
  <p>10.2</p>
  </td>
 <td valign=top width=67% style="height:43.65pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Revolving Promissory Note, dated April 30,&#160; 2012, issued
  by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.3</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement, dated as of April 30, 2012, by Medytox
  Medical Marketing &amp; Sales, Inc. in favor of TCA Global Credit Master
  Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.4</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement. dated as of April 30, 2012, by Medytox
  Diagnostics, Inc. in favor of TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.5</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Guaranty Agreement, dated as of April 30, 2012, by PB
  Laboratories, LLC in favor of TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.6</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Solutions, Inc. and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.7</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Medical Marketing &amp; Sales, Inc. and TCA Global Credit Master
  Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:58.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.8</font></p>
  </td>
 <td valign=top width=67% style="height:58.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between
  Medytox Diagnostics, Inc. and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
<tr style="height:40.5pt;page-break-inside:avoid;">
  <td valign=top width=33% style="height:40.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">10.9</font></p>
  </td>
 <td valign=top width=67% style="height:40.5pt;padding:0in 5.4pt 0in 5.4pt;">
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">Security Agreement, dated as of April 30, 2012, between PB
  Laboratories, LLC and TCA Global Credit Master Fund, LP</font></p>
  <p style="margin:0in;margin-bottom:.0001pt;text-align:justify;"><font face="Times New Roman,serif" style="font-size:12.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table></div>

<p style="margin-bottom:12.0pt;margin-left:1.5in;margin-right:0in;margin-top:0in;text-align:justify;text-indent:-1.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>

<p style="margin-bottom:12.0pt;margin-left:1.5in;margin-right:0in;margin-top:0in;text-align:justify;text-indent:-1.5in;"><font face="Times New Roman,serif" lang=EN-US style="font-size:12.0pt;">&nbsp;</font></p>



</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "msi8k5051912.htm", "secsgml_size_bytes": 38468}]
{"company-data": {"conformed-name": "Medytox Solutions, Inc.", "cik": "0001374536", "assigned-sic": "8734", "irs-number": "542156042", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54346", "film-number": "12855271"}, "business-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401", "phone": "(561) 855-1626"}, "mail-address": {"street1": "400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR", "city": "WEST PALM BEACH", "state": "FL", "zip": "33401"}, "former-company": {"former-conformed-name": "CASINO PLAYERS, INC.", "date-changed": "20060905"}}
M2950303.DOC;1
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 or
15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): May 14, 2012
Medytox Solutions,
Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Nevada
(State
or Other Jurisdiction of Incorporation)
000-54346
54-2156042
(Commission File
  Number)
(I.R.S. Employer
  Identification No.)
400 S. Australian
  Avenue, Suite 800, West Palm Beach, Florida
33401
(Address of
  Principal Executive Offices)
(Zip Code)
(561) 855-1626
(Registrant's
  Telephone Number, Including Area Code)
(Former Name or
  Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 1 –
Registrant's Business and Operations
Item
1.01.  Entering into a Material Definitive Agreement
On May 14,
2012, Medytox Solutions, Inc. ("Medytox") borrowed $550,000 from TCA
Global Credit Master Fund, LP (the "Lender") pursuant to the terms of
the Senior Secured Revolving Credit Facility Agreement, dated as of April 30,
2012 (the "Credit Agreement"), among Medytox, Medytox Medical
Marketing & Sales, Inc. ("Medytox Medical"), Medytox Diagnostics,
Inc. ("Diagnostics"), PB Laboratories, LLC ("PB Labs") and
the Lender.  The funds will be used for general corporate purposes.  Under the
Credit Agreement, Medytox may borrow up to an amount equal to the lesser of 80%
of its Eligible Accounts (as defined in the Credit Agreement) and the revolving
loan commitment, which initially is $550,000.  Medytox may request that the
revolving loan commitment be raised by various specified amounts at specified
times, up to a maximum of $4,000,000.  In each case, the decision to grant any
such increase in the revolving loan commitment is in the Lender's sole
discretion.  The loan matures on the earlier of November 30, 2012, subject to a
six-month extension at the request of Medytox, or upon 60 days written notice
by the Lender.  The maturity date may also be extended, in the Lender's sole
discretion, in connection with an increase in the revolving loan commitment.
The loan bears
interest at the rate of 12% per annum.  In addition, Medytox will pay certain
fees, as set forth in the Credit Agreement.  Medytox also issued to the Lender
40,000 shares of its restricted common stock as a fee for corporate advisory
and investment banking services provided by the Lender.
The loan is
guaranteed by Medytox Medical, Diagnostic and PB Labs, subsidiaries of
Medytox.  It is also secured by a pledge of substantially all of the assets of
Medytox, Medytox Medical, Diagnostic and PB Labs.
The Credit Agreement
imposes certain restrictions on Medytox, including on its ability to (i) incur
any Funded Indebtedness (as defined in the Credit Agreement), (ii) incur liens,
(iii) make investments, (iv) permit a Change in Control (as defined in the
Credit Agreement) or dispose of all or substantially all of its assets, (v)
make capital expenditures not in the ordinary course of its business, (vi)
issue or distribute capital stock, (vii) make distributions to its
shareholders, (viii) engage in any line of business other than the business
engaged in on the date of the Credit Agreement and businesses reasonably
related thereto, and (ix) enter into transactions with any affiliates except in
the ordinary course of business and upon fair and reasonable terms that are no
less favorable to Medytox than it would obtain in an arm-length's basis with a
non-affiliate.  Each of these restrictions is subject to certain exceptions, as
specified in the Credit Agreement.
The loan may
be accelerated upon the occurrence and during the continuation of an Event of
Default (as defined in the Credit Agreement), including nonpayment of amounts
owed, misrepresentation, failure to perform under the Credit Agreement or
related documents, default under certain other obligations, events of bankruptcy,
the entry of a judgment in excess of certain specified amounts, the occurrence
of a Material Adverse Effect (as  defined in the Credit Agreement), the
occurrence of a Change in Control (as defined in the Credit Agreement), certain
impairments of collateral, and the determination in good faith by the Lender
that the prospect for payment or performance of the Obligations (as defined in
the Credit Agreement) is impaired for any reason.
There are no
material relationships between Medytox or any of its affiliates and the Lender,
other than with respect to the Credit Agreement.
The foregoing
is qualified in its entirety by reference to the Credit Agreement, a copy of
which is filed herewith as Exhibit 10.1, the revolving promissory note, a copy
of which is filed herewith as Exhibit 10.2, the Guaranty Agreements, copies of
which are filed herewith as Exhibits 10.3, 10.4 and 10.5, and the Security
Agreements, copies of which are field herewith as Exhibits 10.6, 10.7, 10.8 and
10.9.
Section 2 – Financial Information
Item 2.03. Creation of a Direct Financial Obligation or
an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth above in Item 1.01 is
incorporated by reference.
Section 9 – Financial
Statement and Exhibits
Item 9.01.
Financial Statements and Exhibits
(d)  Exhibits
Exhibit Number
Description
10.1
Senior Secured Revolving Credit Facility Agreement, dated
  as of April 30, 2012, among Medytox Solutions, Inc., Medytox Medical
  Marketing & Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC
  and TCA Global Credit Master Fund, LP
10.2
Revolving Promissory Note, dated April 30,  2012, issued
  by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP
10.3
Guaranty Agreement, dated as of April 30, 2012, by Medytox
  Medical Marketing & Sales, Inc. in favor of TCA Global Credit Master
  Fund, LP
10.4
Guaranty Agreement. dated as of April 30, 2012, by Medytox
  Diagnostics, Inc. in favor of TCA Global Credit Master Fund, LP
10.5
Guaranty Agreement, dated as of April 30, 2012, by PB
  Laboratories, LLC in favor of TCA Global Credit Master Fund, LP
10.6
Security Agreement, dated as of April 30, 2012, between
  Medytox Solutions, Inc. and TCA Global Credit Master Fund, LP
10.7
Security Agreement, dated as of April 30, 2012, between
  Medytox Medical Marketing & Sales, Inc. and TCA Global Credit Master
  Fund, LP
10.8
Security Agreement, dated as of April 30, 2012, between
  Medytox Diagnostics, Inc. and TCA Global Credit Master Fund, LP
10.9
Security Agreement, dated as of April 30, 2012, between PB
  Laboratories, LLC and TCA Global Credit Master Fund, LP
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: May 18, 2012                                                    MEDYTOX
SOLUTIONS, INC.
/s/
William G. Forhan
William
G. Forhan,
CEO
and Chairman
(principal
executive officer)
EXHIBIT INDEX
Exhibit No.
Description
10.1
Senior Secured Revolving Credit Facility Agreement, dated
  as of April 30, 2012, among Medytox Solutions, Inc., Medytox Medical
  Marketing & Sales, Inc., Medytox Diagnostics, Inc., PB Laboratories, LLC
  and TCA Global Credit Master Fund, LP
10.2
Revolving Promissory Note, dated April 30,  2012, issued
  by Medytox Solutions, Inc. to TCA Global Credit Master Fund, LP
10.3
Guaranty Agreement, dated as of April 30, 2012, by Medytox
  Medical Marketing & Sales, Inc. in favor of TCA Global Credit Master
  Fund, LP
10.4
Guaranty Agreement. dated as of April 30, 2012, by Medytox
  Diagnostics, Inc. in favor of TCA Global Credit Master Fund, LP
10.5
Guaranty Agreement, dated as of April 30, 2012, by PB
  Laboratories, LLC in favor of TCA Global Credit Master Fund, LP
10.6
Security Agreement, dated as of April 30, 2012, between
  Medytox Solutions, Inc. and TCA Global Credit Master Fund, LP
10.7
Security Agreement, dated as of April 30, 2012, between
  Medytox Medical Marketing & Sales, Inc. and TCA Global Credit Master
  Fund, LP
10.8
Security Agreement, dated as of April 30, 2012, between
  Medytox Diagnostics, Inc. and TCA Global Credit Master Fund, LP
10.9
Security Agreement, dated as of April 30, 2012, between PB
  Laboratories, LLC and TCA Global Credit Master Fund, LP